Beximco Pharmaceuticals Ltd
BXP
ISIN null / Valor 2318407
Beximco Pharmaceuticals Ltd
UMushroom community rating:
About company
Beximco Pharmaceuticals Ltd., established in 1976 and headquartered in Dhaka, Bangladesh, is a prominent manufacturer and exporter of medicines and active pharmaceutical ingredients (APIs). Initially, the company began by importing and selling products from Bayer AG and Upjohn Inc. in the local market, later transitioning to manufacturing these products under licensing agreements in 1980. By 1983, Beximco Pharma had launched its own formulation brands. Over the years, the company has expanded significantly, now exporting to over 50 countries, including highly regulated markets such as the USA, Europe, Canada, and Australia. Beximco Pharma's manufacturing facilities are accredited by leading global regulatory authorities. The company employs over 4,700 professionals across various disciplines. In recent strategic moves, Beximco Pharma acquired a majority stake in Sanofi Bangladesh Limited in 2021, which was subsequently renamed Synovia Pharma PLC. The company is also notable for being the only Bangladeshi firm listed on the AIM of the London Stock Exchange.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (02.02.2026):
Beximco Pharmaceuticals Ltd — reporting its second quarter of 2024-25 (October–December 2024) and half-year results (six months ended 31 December 2024). The company delivered revenue and profit growth: H1 net sales rose 8.8% to BDT 24,013.4m and profit after tax increased 17.5% to BDT 3,535.0m. Q2 (Oct–Dec 2024) showed stronger sequential growth with sales up 12.8% to BDT 12,299.6m and PAT up 27.9% to BDT 1,843.1m. Operational expansion and export momentum were highlighted alongside continued capital investment.
Key financials — Half year (Jul–Dec 2024)
Net revenue: BDT 24,013.4m (+8.8% y/y). Profit after tax: BDT 3,535.0m (+17.5% y/y). EPS (H1): Tk. 7.87 (vs 6.69). Gross profit BDT 10,978.6m (gross margin ~45.7%); operating profit BDT 5,087.6m (operating margin ~21.2%).
Quarter performance — Q2 (Oct–Dec 2024)
Net sales: BDT 12,299.6m (+12.8% y/y). Profit after tax: BDT 1,843.1m (+27.9% y/y). EPS (Q2): Tk. 4.10 (vs 3.21). Q2 PAT margin ~15.0%, slightly above the H1 average.
Sales mix and international growth
Domestic sales drove the bulk of revenue: Domestic BDT 22,262.3m (+7.4% y/y). Export sales rose strongly by 31.6% to BDT 1,751.1m; company completed 28 new registrations and commenced exports to Cuba, Malta, Qatar and Angola.
Cash flow, capex and balance sheet
Net cash from operations: BDT 2,734.8m (down from BDT 4,467.7m a year earlier). Capex (PPE + intangibles) in H1: ~BDT 1,655.6m. Cash & equivalents at 31 Dec 2024: BDT 1,655.3m. Total assets BDT 73,802.2m; total equity BDT 53,629.0m. NAV per share Tk. 111.35 (up from Tk. 101.11 at Dec-23).
Capital returns and liabilities
Dividend: H1 shows a cash dividend adjustment reducing retained earnings by BDT 1,784.4m and dividend payable of BDT 1,895.3m recorded at 31 Dec 2024. Total liabilities BDT 20,173.2m; long-term borrowings (net current maturity) BDT 2,024.5m with short-term borrowings BDT 3,060.4m.
Operational highlights and outlook comment
Launched four new products in Bangladesh, 28 new registrations of 27 products across 5 countries, and began exports to four new markets. Management flagged continued momentum and focus on international expansion despite macro challenges.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
255 M
Market cap (USD)
Daily traded volume (Shares)
0.34 / 0.34
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
